

Mexico City, April 15, 2015

GENOMMA LAB ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS AND COMMITTEES

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) announces that yesterday, in its General Ordinary Annual Shareholders’ Meeting, the following changes to the Board of Directors and Committees of the Company were approved.

The following executives have been integrated as proprietary members of the Board of Directors:

Leandro Martín Sigman Gold. Chief Executive Officer of Chemo Corporation. Mr. Sigman has a vast experience in the areas of Marketing and Sales, Intelligence and Business Development and Strategic Planning. He worked as Executive Director at Laboratorios Elea and as Marketing Director at Parke-Davis Argentina. Mr. Sigman has a bachelor degree in Economics and a bachelor degree in Journalism, as well as a Master’s in Business Administration from the Instituto de Altos Estudios Empresariales (IAE) Universidad Austral of Buenos Aires, Argentina. He is President of the Chamber of Commerce of Argentina in Spain.

Scott R. Emerson. Founder and President of The Emerson Group and its subsidiaries, Emerson Healthcare and Emerson Marketing. Mr. Emerson has over 30 years of experience in management positions in the areas of brand management, new business development, sales operations and field sales in companies listed in Fortune 500, including Johnson & Johnson, Unilever and Novartis Consumer Health. He sits on the Board of Directors of the Consumer Health Products Association, National Association of Chain Drug Stores, Efficient Collaborative Retail Marketing, among others. He received his Master’s Degree in Accounting from Texas State University.

Roberto Simón Sauma. Dr. Simón has a Master’s Degree in Medicine from the Universidad Nacional Autónoma de México. Management Director of Hospital Ángeles del Pedregal from 1986 to 1994. Chief Executive Officer of Hospital Ángeles del Pedregal from 1995 to 1997. Executive Director at the Corporate of Grupo Empresarial Ángeles, S.A. de C.V. from 1998 to 1999. Health Division Executive Director of Grupo Empresarial Ángeles, S.A. de C.V. from 1999 to 2000. Chief Executive Officer of Grupo Ángeles Servicios de Salud, S.A. de C.V. from 2000 to date.

Additionally, the Company informs the resignation of Mr. Gerardo de Nicolás Gutiérrez as proprietary member of the Board of Directors, member of the Corporate Practices Committee and President of the Risk Committee of Genomma Lab, and of Mr. Julio Everardo Sotelo Morales as proprietary member of the Board of Directors and member of the Risk Committee of Genomma Lab.

Given the above, as of yesterday, the Board of Directors of Genomma Lab is integrated by the following members: Rodrigo Alonso Herrera Aspra as Chairman, Scott R. Emerson, Leandro Martín Sigman Gold,

Contact:

Investor Relations
Tel: +52 (55) 5081 0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Roberto Simón Sauma, Arturo José Saval Pérez, Luis Alberto Harvey MacKissack, José Luis Fernández Fernández, Andrés Conesa Labastida, Jorge Ricardo Gutiérrez Muñoz, Juan Alonso and Sabrina Lucila Herrera Aspra. All of them, except for Mr. Rodrigo Alonso Herrera Aspra and Mrs. Sabrina Lucila Herrera Aspra, are independent members of the Board.

Also, the Corporate Practices Committee is integrated by the following members: Arturo José Saval Pérez as President, Leandro Martín Sigman Gold and Roberto Simón Sauma. The Auditing Committee is integrated by: José Luis Fernández Fernández as President, Luis Alberto Harvey MacKissack and Jorge Ricardo Gutiérrez Muñoz.

Rodrigo Herrera Aspra, Chairman of the Board and Chief Executive Officer, commented: “We welcome with great satisfaction the new members of the Board of Directors, with the certainty that with their experience, capacity and professional prestige, they will enrich and positively feedback such body.”

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low - cost, highly flexible supply chain operating model.

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.